Every article is dated and numbered by version. When we correct something, the correction stays on the page instead of quietly disappearing into the text.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
An open study found sleep normalised in six of seven patients. The controlled study by the same investigator found weak effects and said so. The difference between them is a placebo arm.
It does not raise dopamine — it magnifies what other things do to it. That one property explains why caffeine feels stronger on it, and why MAO inhibitors are a hard contraindication.
Licensed in Russia since 2009, with human trials matching a benzodiazepine without the sedation. Nearly all of the evidence comes from a single research tradition — and the route you use changes the pharmacology.
Approved in 35 countries, 11,000 subjects, 30 trials. Then its largest randomised trial found nothing — and a meta-analysis showed exactly where the apparent benefit had been coming from.
KPV has the most specific mechanism of anything in this section, and a delivery route that inflamed tissue upregulates on its own. It is also there to fix a problem the blend creates.
Each component's evidence stops somewhere different. The claim that they combine well has no study behind it at all — and the best-supported benefit of blending is tolerability, not healing.
Randomised human evidence, a cosmetic shelf position, and an FDA restriction all attach to the same molecule — depending on the route. The clinical results quoted for the injection came from the topical.
The number every dosing schedule is built on has no published source. And the cancer reassurance that works for BPC-157 does not transfer to this one.
A 2025 review found 36 studies in sports medicine — 35 preclinical, one in humans. The mechanism is detailed and coherent. The human evidence is three small pilots and a cancelled trial.
The synergy between the two pathways is demonstrated in humans. The outcomes people buy it for are not — no trial has measured body composition or recovery from the combination.
One clears in half an hour and makes a pulse. The other binds albumin and holds a plateau for a week. And the version almost nobody uses is the only one with human trial data.
Same receptor, same pathway, same cascade as every other GHRH analogue. What differs is what was measured — and one storage property that a purity test cannot detect.
The original GHRH analogue, cleared by the FDA in 1997 and withdrawn for commercial reasons. Its short half-life is both its weakness and the reason it behaves naturally.
It raises growth hormone without the cortisol and prolactin that older compounds in its class produce. It also failed its only controlled clinical trial.
Two structural changes stop binding proteins capturing it, tripling potency and doubling half-life. The same edits remove the controls that existed for a reason.
Not a peptide, never tested in a human, and sold at a fraction of the studied dose in a form that may not absorb. The mechanism is real; almost nothing else is settled.
A small molecule, not a peptide. It targets a drain on NAD+ that only exists in fat tissue — and only when that drain is already overexpressed.
Sixteen amino acids encoded outside the nucleus, acting through AMPK and travelling to the nucleus to change gene expression. Roughly 200 animal studies, and one human trial of an analogue.
GLP-1 and GIP together, an approved medicine, and the assumption the field got backwards. Plus the drug interaction most people miss.
One molecule acting on GLP-1, GIP and glucagon receptors at once. What each contributes, what the trials measured, and why it suppresses appetite less than semaglutide.
Moisture, heat, light and oxygen, and what each one actually does. Plus the distinction that resolves most storage arguments: microbial safety and chemical stability are two different clocks.
Molecular size, a fifteen-minute clearance window, and a 150-microlitre ceiling decide it. Not formulation effort.
Aim at the glass, never at the powder. Swirl, never shake. The short procedure for putting a dried peptide back into solution, and the reason behind each rule.
Milligrams, micrograms, millilitres and International Units — the conversions, the concentration formula, and the thousand-fold error that matters most.
For most research peptides there is no long-term human safety record. Not a poor one — an absent one. Here is what that means.
Five questions that separate evidence from marketing, none of which need a science background. Apply them to this site too.
Amino acids, the bond that links them, and why the order they sit in decides everything that happens later.
Steroids add a hormone to your body. Peptides carry an instruction. The difference decides what each can and cannot do.
Shape decides everything. A peptide binds a receptor, a second messenger amplifies the signal, and a small amount goes a long way.
Digestion exists to break peptides into amino acids. A swallowed peptide is taken apart before it can reach anything.
A 99% figure describes the light absorbed at one wavelength, not the mass in the vial. Here is what HPLC misses, and which tests close each gap.
Purity, net peptide content, counterion, moisture: four different numbers. Reading the first as though it were the second is the costly mistake.
Most “ships fine at room temperature” claims rest on transit studies of a few days. That is a different question from how long it keeps.
Anchor, deprotect, couple, cleave. Understanding the loop explains why deletion sequences are the main impurity in most batches.
RUO is a legal classification, not a quality mark. No test is run to earn it, and it says nothing about sterility, endotoxin, or heavy metals.
Measured mass against calculated mass. A gap of +16, +42, +71 or −18 daltons each points at a specific, well-known cause.
LAL finds soluble Gram-negative endotoxin down to picogram levels. It says nothing about sterility, fungi, solvents, or anything alive.
The terms that turn up most often on peptide paperwork, defined plainly, with links to the articles that cover them in full.
Flip one amino acid to its mirror form and the mass is unchanged and the purity figure is unchanged. Only a test built for it will find it.
Hydrolysis, oxidation, aggregation. What drives each one, and which test it shows up on — because none of them shows up on all three.
Official handbooks set limits for established medicines. Where no entry exists, the numbers come from a four-stage process, or from the supplier.
Counterions, water, and leftover solvent make up the rest of the powder. Three separate methods are needed to measure them, and HPLC is not one.
